Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | MLNR | O43193 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30050074 | 1.00 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2GAAHSD17B10KDM4E | |
| SCHEMBL30049877 | 0.95 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2GAAHSD17B10KDM4E | |
| SCHEMBL27162435 | 0.95 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2GAAHSD17B10KDM4E | |
| SCHEMBL30049539 | 0.94 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2GAAHSD17B10KDM4E | |
| SCHEMBL27162286 | 0.94 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2GAAHSD17B10KDM4E | |
| SCHEMBL30048847 | 0.90 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2GAAHSD17B10KDM4E | |
| SCHEMBL27161957 | 0.90 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2GAAHSD17B10KDM4E | |
| SCHEMBL27162113 | 0.89 | GAA (0.45) | ALDH1A1SMN1; SMN2GAAHSD17B10KDM4E | |
| SCHEMBL30049856 | 0.88 | GAA (0.43) | ALDH1A1SMN1; SMN2GAAHSD17B10KDM4E | |
| SCHEMBL27162782 | 0.88 | GAA (0.43) | ALDH1A1SMN1; SMN2GAAHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4330248-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | Acondicionamiento Tarrasense (ES) | 2024-03-06 | — | — | EP | claimed |
| US-20240254115-A1 | New Pyridine-Sulfonamide Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-08-01 | — | — | US | disclosed |
| EP-4330248-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | Acondicionamiento Tarrasense (ES) | 2024-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254115-A1 | New Pyridine-Sulfonamide Derivatives as Sigma Ligands | SIGMAR1, TMEM97, OPRD1 | ALDH1A1 1011/4885SMN1; SMN2 3118/4885GAA 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.